|Videos|January 9, 2023
Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment
Author(s)Hans Hammers, MD, PhD, Moshe Ornstein, MD
Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR TKI–pretreated advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
4
The OncFive: Top Oncology Articles for the Week of 8/16
5